ABCL-503 Golcadomide (GOLCA; CC-99282), a Potential First-in-Class Oral CELMoD™ Agent, With R-CHOP, As First-line (1L) Therapy in Aggressive B-Cell Lymphoma (a-BCL): Safety and Efficacy in an Open-Label, Multicenter, Phase 1b Trial

Autor: Westin, Jason, Hoffmann, Marc S., Vassilakopoulos, Theodoros, Munoz, Javier L., Jurczak, Wojciech, Yeh, Su-Peng, Zimowska-Curyło, Dagmara, Kwiatek, Michał, Martín García-Sancho, Alejandro, Sudhindra, Akshay, Gkasiamis, Argyrios, Patel, Arpankumar, Boucaud, Floriane, Petel, Adrien, Kaplan, Mark, Basavanhally, Tara, Li, Ju, Nowakowski, Grzegorz

Publikováno v: In Clinical Lymphoma, Myeloma and Leukemia September 2024 24 Supplement 1:S482-S482

Gigwa v2—Extended and improved genotype investigator

Autor: Sempéré, Guilhem, Pétel, Adrien, Rouard, Mathieu, Frouin, Julien, Hueber, Yann, De Bellis, Fabien, Larmande, Pierre

Publikováno v: GigaScience
GigaScience, BioMed Central, 2019, 8 (5), ⟨10.1093/gigascience/giz051⟩
GigaScience 5 (8), . (2019)
GigaScience, 2019, 8 (5), ⟨10.1093/gigascience/giz051⟩

International audience; Background: The study of genetic variations is the basis of many research domains in biology. From genome structure to population dynamics, many applications involve the use of genetic variants. The advent of next-generation s

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::53353589da84ddb94ba6d8f06adf2f90
http://europepmc.org/articles/PMC6511067